Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 272

1.

[How the managing role of the coordinator of nuclear medicine changes due to the new rules on: "Good preparation of the radiodrugs in nuclear medicine"].

Massaro A, De Pieri P, Rubello D, Marcolongo A.

Minerva Med. 2009 Feb;100(1):123-32. Epub 2008 Dec 17. Italian. No abstract available.

PMID:
19088702
2.

Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.

Hung JC, Augustine SC, Cheng KT, Green RL, Hopkins WM, Laven DL, Nelson BR, Petry NA, Ponto JA, Quinton TM, Swanson DP.

J Am Pharm Assoc (Wash). 2002 Sep-Oct;42(5):789-98.

PMID:
12269713
3.

Nuclear medicine affected by Energy Policy Act of 2005.

[No authors listed]

J Nucl Med. 2005 Oct;46(10):12N, 14N. No abstract available.

4.

Exemption of radiopharmaceuticals from <797>.

Hung JC, VanBrocklin HF.

J Nucl Med. 2004 Oct;45(10):14N. No abstract available.

5.

From the SNM Committee on Pharmacopeia: Exemption of radiopharmaceuticals from <797>.

Hung JC; SNM Committee on Pharmacopeia.

J Nucl Med. 2004 Oct;45(10):13N, 16N. No abstract available.

PMID:
15551509
6.

[Maintaining standards of good compounding (N.B.F.)].

Castoldi B, Fumagalli A, Mazzoldi G.

Boll Chim Farm. 1978 Dec;117(12):689-99. Italian. No abstract available.

PMID:
752351
7.

About mentioning quality of preparation and quality control of radiopharmaceuticals used in nuclear medicine procedures.

Wozniak G, Georgoulias P, Archimandritis S, Dimakopoulos N, Fezoulidis I.

Hell J Nucl Med. 2006 Jan-Apr;9(1):41-2. No abstract available.

PMID:
16617394
9.

[The nuclear medicine specialist, expert in radiopharmacology. A long and winding road].

Freire J, Banzo J, Martín-Comín J.

Rev Esp Med Nucl. 2001 Dec;20(7):515-6. Spanish. No abstract available.

10.

[Quality control dose calibrators].

Montoza Aguado M, Delgado García A, Ramírez Navarro A, Salgado García C, Muros de Fuentes MA, Ortega Lozano S, Bellón Guardia ME, Llamas Elvira JM.

Rev Esp Med Nucl. 2004 Nov-Dec;23(6):434-43. Spanish.

11.

Deficiencies of product labeling directions for the preparation of radiopharmaceuticals.

Hung JC, Ponto JA, Gadient KR, Frie JA, Aksamit CM, Enquist CL, Carrels KE.

J Am Pharm Assoc (2003). 2004 Jan-Feb;44(1):30-5.

PMID:
14965150
12.

USP general chapter <797> pharmaceutical compounding-sterile preparations.

Hung JC.

J Nucl Med. 2004 Jun;45(6):20N, 28N. No abstract available.

13.

Pharmacy compounding: background on the latest federal initiatives.

Nichols D.

J Nucl Med. 1998 Jan;39(1):26N. No abstract available.

14.

CGMP for PET drugs: important steps to take now.

Vanbrocklin H, Schwarz S.

J Nucl Med. 2010 Dec;51(12):17N. No abstract available.

15.

[On the situation of permit free self-production of radiopharmaceuticals in nuclear medicine].

Hoppe U, Machulla HJ, Neumaier B.

Nuklearmedizin. 2013;52(5):N53-4. German. No abstract available.

PMID:
24085459
16.

Compounding language drafted by congress.

Nichols D.

J Nucl Med. 1997 Apr;38(4):23N-24N. No abstract available.

PMID:
9098189
17.

Current good manufacturing practices for PET drug products in the United States.

Swanson D, Graham M, Heinonen TM, Libby P, Mills GQ.

J Nucl Med. 2009 Aug;50(8):26N-8N. No abstract available.

18.

The future of USP monographs for PET drugs.

Schwarz S, Norenberg J, Berridge M, Dragotakes S, Hung J, Link J, Mason NS, Mattmuller S, Nickel RA, Packard A, Paolino J, Petry N, Ponto J, Quinton TM, Seifert KL, Swanson D, Weiner RE, Zigler S.

J Nucl Med. 2013 Mar;54(3):472-5. doi: 10.2967/jnumed.112.115089. Epub 2012 Dec 21. No abstract available.

19.

Radionuclide calibrator comparisons and quality improvement in nuclear medicine.

Oropesa P, Woods MJ, Olsovcová V, dos Santos JA.

Appl Radiat Isot. 2008 Mar;66(3):353-61. Epub 2007 Jul 20.

PMID:
17855099

Supplemental Content

Support Center